given once-daily for four consecutive days. Data from this multiple
dose trial are intended to support the continued development of
tezampanel for the treatment of migraine, as well as allow TorreyPines
to consider expanding the development of tezampanel into additional
chronic pain conditions.
-- Completed a Phase I multiple-dose clinical trial of NGX267 in
development for cognitive impairment associated with schizophrenia
(CIAS). NGX267 was found to be safe and well-tolerated. The clinical
trial also demonstrated that NGX267 increases salivary flow, which may
be beneficial in treating xerostomia, or dry mouth.
-- Extended the genetics discovery collaboration with Eisai Co., Ltd.
This agreement focuses on the discovery of Alzheimer's disease targets
using whole-genome family-based association screening. Under terms of
the agreement, TorreyPines received an upfront payment and continued
research funding in support of the program for an additional year.
Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.
Revenue for the nine month period ended September 30, 2007 was $7.4
million compared to revenue of $7.4 million for the same period in 2006.
Operating expenses for the nine month period were $24.6 million, with $20.4
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved